Targeted Patient Leverage nangibotide's focus on high-need inflammatory syndromes such as septic shock and severe COVID-19 to position a specialized outreach to hospital systems, ICUs, and infectious disease departments that manage acute inflammatory conditions.

Companion Diagnostic Highlight the existing collaboration with Roche Diagnostics for the sTREM-1 Companion Diagnostic to identify patients most likely to benefit, offering a data-driven sales narrative around precision medicine and improved clinical outcomes.

Regulatory Advantage Capitalize on regulatory progress including EMA PRIME and FDA Fast Track status to build credibility with payers and hospital administrations, framing nangibotide as a prioritized candidate with a clear development pathway.

Strategic Partnerships Engage potential partners in diagnostics, biopharma, and biotech enabling monoclonal antibody expansion by presenting Inotrem’s broader pipeline and the new antibody program as co-development or licensing opportunities.

Global Expansion Position to support international clinical trials and potential commercialization through partnerships or distributor networks as Inotrem scales from Phase II to registration-ready programs, aligning with global tenders and government-funded initiatives.